Phase Ib Trial of Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate
Latest Information Update: 17 Jun 2025
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Docetaxel; Etoposide
- Indications Bladder cancer; Neuroendocrine carcinoma; Prostate cancer; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 19 Sep 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2026.
- 19 Sep 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2025.
- 19 Sep 2024 Status changed from completed to active, no longer recruiting.